Nature Reviews Drug Discovery

Article	Citations
AI serves up target and inhibitor for lung fibrosis	2231
Vaccine exposes tumours to immune cell attack	1309
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	858
The importance of persistence in cancer drug development	738
A specific biomarker for insoluble tau	700
Targeting tumour-associated bacteria	574
A new path to targeted protein degradation?	550
Neutralizing Zika virus	544
The improving benefit–risk balance of phase I cancer trials	519
FDA approves a c-MET-targeted ADC for lung cancer	493
Tumour cells get a dendritic cell makeover	480
Glucose-sensitive insulin protects against hypoglycaemia	454
Promoting tissue repair after heart attack	434
mRNA-encoded monoclonal antibody fights CHIKV	414
Hypoimmune iPSCs escape immune detection	394
Lipid nanoparticle ferries therapeutic mRNA to the placenta	382
Targeting drug-resistant glioblastoma	347
Degrading cell-free DNA to prevent recurrent stroke	340
New antibiotic for urinary tract infections nabs FDA approval	314
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	304
Anti-tau antibody stumbles in phase II Alzheimer trial	300
Evolution of innovative drug R&D in China	300
FDA new drug approvals in Q1 2023	278
Targeting the Hippo pathway in cancer	277
Top companies and drugs by sales in 2021	276

Apolipoprotein L2 inhibitor mitigates fibrosis	269
FDA approves second TTR stabilizer for cardiac amyloidosis	269
Chemical engineering of CRISPR–Cas systems for therapeutic application	269
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	253
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	253
2022 FDA approvals	239
Small-molecule discovery through DNA-encoded libraries	231
Increasing the potency of T cell therapies	223
mRNA vaccines for infectious diseases — advances, challenges and opportunities	223
Small molecule improves muscle function in myasthenia gravis	219
Blocking breast cancer metastasis	204
Reflections on 10 years of the FDA’s breakthrough therapy designation	203
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	202
Pushing both sides of the drug pricing aisle	191
Host-directed antiviral blocks SARS-CoV-2 entry	188
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	179
TCR-engineered T cells get personal	179
FDA new drug approvals in Q2 2023	178
The antibody–drug conjugate landscape	173
Base editors hit the clinic	166
The significance of blockbusters in the pharmaceutical industry	163
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	163
Inhibiting ASGR1 boosts cholesterol removal	152
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	151
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	148
Amylin takes another shot at the obesity prize	145
Rewired proteostasis in KRAS inhibitor resistance	141
R&D re-balancing act	137
A call to action for translational sciences in COVID-19 and future pandemics	136
Mimicking the health benefits of exercise	135
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	134
Pan-coronavirus vaccine pipeline takes form	134
Screening ultra-large virtual libraries	132
FDA approves second BCMA-targeted CAR-T cell therapy	119
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	118
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	112
The emerging role of mass spectrometry-based proteomics in drug discovery	110
Combating antimicrobial resistance in malaria, HIV and tuberculosis	108
Phenotypic drug discovery: recent successes, lessons learned and new directions	104
Antibody–drug conjugates come of age in oncology	102
Multi-TACs target solid tumours	99
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	98
The malignant melanoma market	97
Immunology on the brain	96
Gut metabolite mediates nerve repair	96
Reducing IL-2 toxicity	95
Agonist antibody lowers blood pressure	90
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	90
LRRK2-targeted Parkinson disease drug advances into phase III	88
Monkeypox mRNA vaccine protects mice and macaques	87

Anti-IL-11 antibody shows anti-ageing properties	83
Neglected tropical diseases go global	83
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	82
The European Innovation Network as a hub for medicines innovation in Europe	81
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	78
Ribosome inhibitor combats bacterial drug resistance	78
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	77
Frameworks for transformational breakthroughs in RNA-based medicines	76
Avidity in antibody effector functions and biotherapeutic drug design	76
Engineered parasite delivers proteins to the brain	75
Delivering genome editing tools to primary cells	73
Engineering a compact genome-editing tool	73
RNA structure guides antiviral ASO design	71
Upcoming market catalysts in Q4 2023	71
Investigating the origins of recent pharmaceutical innovation	70
Covalent inhibitor engages oncogenic AKT kinase	69
A rush of CRISPR to the lungs	68
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	64
Accelerating precision oncology by converging pragmatic trials and real-world evidence	64
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	64
Promoting efferocytosis heals diabetic wounds	63
Publisher Correction: Roflumilast	62
The non-small-cell lung cancer drug market	61
MYC in cancer: from undruggable target to clinical trials	61
Trends in the development of cellular and gene therapy in China	59
Broader horizons for cereblon glue degraders	55
FDA approves first PSMA-targeted radiopharmaceutical	53
Targeting protein disorder: the next hurdle in drug discovery	52
AAV-based in vivo gene therapy for neurological disorders	51
Identification of neoantigens for individualized therapeutic cancer vaccines	51
Three-step cures for autoimmune diseases?	50
A bacteria-derived oral tumour vaccine	48
V-ATPase inhibitor targets Ras-mutant cancers	47
RNA delivery heats up cold tumours	45
Upcoming market catalysts in Q4 2024	45
Microbial ‘dark matter’ yields new antibiotic	44
Can large, simple trials bring drug developers back to common diseases?	43
Designing novel macrocyclic drugs	43
Towards a broad-spectrum antiviral agent	43
Novel strategies to manage CAR-T cell toxicity	41
Analysis of China-to-West pharmaceutical licensing deals in 2024	40
The market for ulcerative colitis	38
Cartilage regeneration for osteoarthritis	37
The case for cell-penetrating peptides	36
RNA chemistry and therapeutics	35
Neurotensin receptor modulator safely tackles pain	35
Understanding LAG3 immune checkpoint function	34
De novo design of macrocycles	34
FDA approves cell-sheet-based gene therapy for severe skin disease	34
Hinge modifier approach opens door to drugging HECT E3 ligases	33
A new drug target for NRAS(Q61) mutant-expressing cancers	32
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	32
PPAR agonists provide new treatment options for inflammatory liver disease	32
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	31
2023 FDA approvals: unprecedented volume at moderate value	31
Glue-based KRAS inhibitors make their debut cancer trial mark	31
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	30
The evolution of the obesity drug market	30
Therapeutically harnessing extracellular vesicles	30
A faster route to antidepressant activity	29
Refining HIV pre-exposure prophylactic agents	29
Synthetic cytokine circuit targets solid tumours	29
Targeting sigma receptor 1 in long QT syndrome	28
Designing closure-stabilizing integrin inhibitors	26
Designing a novel synthetic receptor	26
Transcription reprogramming to enhance CAR-T cell function	26
miR-21 antagomir reverses COPD pathology	26
Publisher Correction: Evolution of the market for mRNA technology	25
A step closer to in vivo editing of haematopoietic stem cells	25
Novel schizophrenia therapy filed for FDA approval	25
FDA approves first factor XIIa inhibitor, for hereditary angioedema	24
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	24
Enhancing CAR-T cell efficacy through IFN ablation	24
PD1 × VEGF blocking bispecifics for cancer draw big backing	23
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	23
FDA approves 21-valent pneumococcal vaccine	23
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	22
FDA approves decades-old maribavir for CMV infection	22
CAR T cells take to the airways	21
Improving efficacy of ASO therapy in SMA	21

Rebalancing cardiolipin biosynthesis to treat cardiomyopathy	20
FDA approves PI3Kα inhibitor that does double duty as a degrader	20
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	20
Anti-histamines boost immunotherapy	20
RNAi-based drug design: considerations and future directions	19
Sequential immunotherapy: towards cures for autoimmunity	19
Top product forecasts for 2025	19
Unmet needs in vaccine development	19
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	19
Targeting galectin-driven regulatory circuits in cancer and fibrosis	18
In vivo CAR T cells move into clinical trials	18
Drugging the efferocytosis process: concepts and opportunities	18
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	17
Synthesizing portimines	17
Genome-editing medicinal products: the EMA perspective	17
Acyl-lysine reader inhibitor blocks AML progression	17
Treating cannabis use disorder	17
Understanding the effects of antibiotic combinations	17
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	17
Open-science drug discovery for COVID-19	17
Bacteria tag tumours for CAR-T cell attack	16
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	16
Epigenetic editor silences prion protein	16
Stalled molecular motor inhibits tumour growth	16
Rediscovering hygromycin A for Lyme disease treatment	16
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	15
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	15
Building on the momentum of N-of-1 base editor therapies for rare diseases	15
opnMe.com: a digital initiative for sharing tools with the biomedical research community	15
Brain glucose mediates amphotericin B tolerance	15
ASO targets DNA repair protein to combat Huntington disease	15
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	15
Trustworthy AI for safe medicines	15
Insights into new approach methodology innovation: an EMA perspective	15
Thinking outside the box: non-canonical targets in multiple sclerosis	15
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning	14
mRNA flu shots move into trials	14
The KRAS crowd targets its next cancer mutations	14
Advanced technologies for the development of infectious disease vaccines	14
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	13
A type 1 regulatory T cell-based therapy	13
Trends in the drug target landscape for autoimmune diseases	13
Neurons give metastatic cells a push	13
In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics	13
Bispecific antibodies in oncology	13
Alnylam scores big pharma support for angiotensinogen silencer	13
Gene editing addresses antithrombin deficiency	12
Understanding sphingosine-1-phosphate transport	12
Understanding immunomodulatory antibody agonism	12
A new antibiotic for A. baumannii	12
Antibody cocktail eliminates ebolaviruses	12
FDA releases tissue-agnostic cancer drug draft guidance	12
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	12
Phosphatase inhibitor drives anticancer immune responses	11
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	11
Top product forecasts for 2022	11
Targeting ALDH1B1 in colorectal cancer	11
Soluble Notch agonists drive T cell production	11
The renal cell carcinoma drug market	11
Setting GPCRs free	11
Ramping up mitochondrial DNA replication	10
FDA approves first two drugs for rare Niemann–Pick disease	10
Macrophages as tools and targets in cancer therapy	10
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities	10
Hooking FSH as a potential target for Alzheimer disease	10
FDA approves first chikungunya vaccine	10
DUBTACs for targeted protein stabilization	10
Targeting cytokine networks in neuroinflammatory diseases	10
Upcoming market catalysts in Q3 2023	10
FDA approves first claudin-18.2-targeted antibody for gastric cancer	10
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	10
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	9
Inhibiting metallo-β-lactamases	9
Mapping cysteine ligandability	9
Membrane transporters in drug development and as determinants of precision medicine	9
Two-pronged approach for macular degeneration	9
mRNA vaccine for Lyme disease prevention	9
Targeting expanded trinucleotide repeats	9
Targeting ephrin signalling in sepsis	9
New therapeutic candidate for Chagas disease	8
Chromatin-targeted drug discovery at “a very special moment”	8
Opportunities for mitochondrial disease gene therapy	8
Antibody drug conjugate combats inflammation	8
BacPROTAC to treat tuberculosis	8
Developing an IKZF2 glue degrader	8
Advances in the treatment of systemic lupus erythematosus	8
Repurposing beta-blockers in breast cancer	8
2022 FDA approval number dips: a COVID-19 hangover?	8
The potential of innovative trial design for efficiently evaluating repurposed drugs	8
Novel drug targets in 2021	8
New route to target RAS	8
FDA approves second anti-amyloid antibody for Alzheimer disease	7
Immune targets for therapeutic development in depression: towards precision medicine	7
Deuterium in drug discovery: progress, opportunities and challenges	7
Novel drug targets in 2023	7